Optimal implementation of adoptive T-cell therapy for cancer will likely require multiple and
maintained genetic modifications of the infused T cells and their progeny so that they home
to tumor sites and recognize tumor cells, overcome tumor immune evasion strategies, and
remain safe. Retroviral vectors readily transduce T cells and integrate into the host cell
genome, but have a limited capacity for multigene insertion and cotransduction and are
prohibitively expensive to produce at clinical grade. Genetic modification of T cells using …